-
公开(公告)号：US11135281B2
公开(公告)日：2021-10-05
申请号：US16315986
申请日：2017-07-07
发明人： David E. Clements , Neal Van Hoeven
IPC分类号： A61K39/12 , A61K31/14 , A61K9/127 , A61K39/39 , A61P31/14 , A61K36/00 , A61K36/73 , A61K39/00
摘要： A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.
-
公开(公告)号：US20190298819A1
公开(公告)日：2019-10-03
申请号：US16315986
申请日：2017-07-07
发明人： David E. Clements , Neal Van Hoeven
摘要： A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.
-
公开(公告)号：US20220160632A1
公开(公告)日：2022-05-26
申请号：US17560594
申请日：2021-12-23
发明人： Christopher B. Fox , Susan S. Lin , Darrick Carter , Neal Van Hoeven , Mayuresh M. Abhyankar , William A. Petri
IPC分类号： A61K9/127 , A61K31/739 , A61K39/39
摘要： Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
-
公开(公告)号：US11266602B2
公开(公告)日：2022-03-08
申请号：US16098619
申请日：2017-05-15
发明人： Christopher B. Fox , Susan S. Lin , Darrick Carter , Neal Van Hoeven , Mayuresh M. Abhyankar , William A. Petri
IPC分类号： A61K9/127 , A61K31/739 , A61K39/39 , A61K39/00
摘要： Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
-
公开(公告)号：US20200085757A1
公开(公告)日：2020-03-19
申请号：US16098617
申请日：2017-05-17
发明人： Neal Van Hoeven , Traci Mikasa , Christopher B. Fox , Anwar Ahniyaz , Mark T. Orr , Amit Khandhar
摘要： Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle N ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
-
公开(公告)号：US11173126B2
公开(公告)日：2021-11-16
申请号：US16098617
申请日：2017-05-31
发明人： Neal Van Hoeven , Traci Mikasa , Christopher B. Fox , Anwar Ahniyaz , Mark T. Orr , Amit Khandhar
摘要： Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
-
公开(公告)号：US11141377B2
公开(公告)日：2021-10-12
申请号：US16622908
申请日：2018-06-15
摘要： Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.021 秒)
